Facebook
Twitter
LinkedIn
ForwardManagement of Newly Diagnosed Multiple Myeloma in Those Eligible for Transplant
This information was originally presented at the NCCN 12th Annual Congress: Hematologic Malignancies™ held in San Francisco, California, on October 6-7, 2017.
Target Audience
This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this activity, participants should be able to:
- Summarize the role of autologous stem cell transplant in the management of patients newly diagnosed with multiple myeloma.
- Select appropriate evidence-based management strategies for patients with newly diagnosed multiple myeloma.
Shaji K. Kumar, MD
Mayo Clinic Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below discloses the following relevant financial relationships:
Shaji K. Kumar, MD
Abbott Laboratories: Grant/Research Support
Amgen Inc.: Grant/Research Support; Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Grant/Research Support; Scientific Advisor
GlycoMimetics: Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Kesios Therapeutics: Consulting Fees, Honoraria
Novartis Pharmaceuticals Corporation: Grant/Research Support
NOXXON Pharma AG: Consulting Fees, Honoraria
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
SkylineDx: Consulting Fees, Honoraria
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Melissa Esplen; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Donald Harting, MA, ELS, CHCP; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD (employed by NCCN until October 30, 2017); Gary J. Weyhmuller, MBA, SPHR
The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Rashmi Kumar, PhD; Dorothy Shead, MS
Definitions
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.50 hours of Category I credit for completing this activity.
Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.41 contact hours.
Pharmacists
| National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.050 CEUs) of continuing education credit. UAN: 0836-0000-17-096-H01-P
Available Credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.41 ANCC contact hours
- 0.50 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing